Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) Income from Continuing Operations (2016 - 2025)

Voyager Therapeutics' Income from Continuing Operations history spans 11 years, with the latest figure at 27426000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 20.47% year-over-year to 27426000.0; the TTM value through Dec 2025 reached 119721000.0, down 84.18%, while the annual FY2025 figure was 119721000.0, 84.18% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 27426000.0 at Voyager Therapeutics, up from 27892000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 124044000.0 in Q1 2023 and bottomed at 34487000.0 in Q4 2024.
  • The 5-year median for Income from Continuing Operations is 22909000.0 (2022), against an average of 8642900.0.
  • The largest annual shift saw Income from Continuing Operations tumbled 566.69% in 2022 before it skyrocketed 681.85% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 5059000.0 in 2021, then crashed by 566.69% to 23610000.0 in 2022, then skyrocketed by 338.86% to 56395000.0 in 2023, then plummeted by 161.15% to 34487000.0 in 2024, then increased by 20.47% to 27426000.0 in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Income from Continuing Operations are 27426000.0 (Q4 2025), 27892000.0 (Q3 2025), and 33382000.0 (Q2 2025).